[go: up one dir, main page]

WO1997038696A1 - Bisphosphonates utilises comme agents anti-inflammatoires - Google Patents

Bisphosphonates utilises comme agents anti-inflammatoires Download PDF

Info

Publication number
WO1997038696A1
WO1997038696A1 PCT/GB1997/001037 GB9701037W WO9738696A1 WO 1997038696 A1 WO1997038696 A1 WO 1997038696A1 GB 9701037 W GB9701037 W GB 9701037W WO 9738696 A1 WO9738696 A1 WO 9738696A1
Authority
WO
WIPO (PCT)
Prior art keywords
bisphosphonate
ibandronate
inflammatory
treatment
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB1997/001037
Other languages
English (en)
Inventor
Anthony Robert Lyons
Sharon Patricia Mary Crouch
David James Phipps
Andrew Wilcock
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Nottingham
Original Assignee
University of Nottingham
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Nottingham filed Critical University of Nottingham
Priority to AU25186/97A priority Critical patent/AU2518697A/en
Publication of WO1997038696A1 publication Critical patent/WO1997038696A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid

Definitions

  • the present invention relates to bisphosphonates as anti-inflammatory agents, and particularly but not exclusively to ibandronate as an anti- inflammatory agent.
  • cytokines Interleukins, Tumour Necrosis Factor
  • the invenuon also provides the use of a bisphosphonate for the preparation of an anti-inflammatory agent for the treatment of disorders.
  • ibandronate for the preparation of an agent for the treatment of chronic immune system activation disorders.
  • the bisphosphonate is used in vitro, and preferably comprises ibandronate.
  • a still further aspect of the present invention provides for the use of bisphosphonates, in particular ibandronate to inhibit pro-mflammatory cytokine production and/or activity.
  • Fig. 1 the effect of ibandronate on TNF secretion (No LPS);
  • Fig. 3 the effect of ibandronate on IL-8 production : lOpg/ml LPS;
  • Fig. 4 the effect of ibandronate on IL-8 secretion (No LPS).
  • IL-1 Interleukin 1
  • IL-lra Intereukin -1 receptor antagonist
  • TNF Tumour Necrosis Factor
  • sTNFRI soluble TNF receptor inhibitor
  • IL-8 lnterleukin-8
  • Ibandronate was seen to inhibit the spontaneous production of TNF however in the presence of LPS there was only significant inhibition after 48 hours of culture which is at the limit for cell viability in this cutlure technique. (Figs. 1 and 2). Ibandronate inhibited IL-8 secretion in a concentration dependent fashion in the presence or absence of LPS. (Figs. 3 and 4). No effect was shown upon the secretion of soluble TNF receptor inhibitor (sTNFRI).
  • sTNFRI soluble TNF receptor inhibitor
  • Ibandronate may act as an anti-inflammatory agent through its inhibitory effects upon IL-8. This may prevent recruitment and activation of inflammatory cells.
  • IL-8 is a potent stimulator of angioneogenesis (new blood vessel formation) at tumour sites and this may be effective in controlling metastatic seeding or growth. No change in the response of the cells was noted when they were first stimulated with LPS. This would suggest that responses to infective processes may be unimpaired and inhibition of the cytokine response would not render subjects immunodefficient.
  • Ibandronate therefore appears to specifically target the TNF and Interleukin-8 pathway to inhibit the production of these pro-inflammatory cytokines, and since cytokines are fundamental to inflammation thereby obviate or mitigate chronic immune system activation inflammation. This not only provides for alleviation of symptoms of many chronic immune system activation disorders, such as cancer, MS and AIDS, but may also provide a basis for keeping such diseases in check or providing a complete cure. Ibandronate can also be used to treat other inflammatory diseases such as rheumatoid arthritis, and also to prevent metastases of cancer.
  • ibandronate has minimal side effects, the only known side effect consisting solely of morning fever.
  • the use of ibandronate in accordance with the present invention will not be associated with the adverse reactions associated with the conventional use of immune suppressants.
  • ibandronate as an anti-inflammatory agent, and for the preparation of an agent for the treatment of chronic immune system activation disease, via the modulation of the activity and cytokine production of immune cells, including lymphocytes and macrophages offers many advantages over known drugs. Since activated macrophages, lymphocytes and pro-inflammatory cytokines are involved in the pathogenesis and generation of symptom burden in disease of chronic immune system activation, ibandronate provides effective treatment for these diseases and their symptoms.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention a pour objet l'utilisation d'un bisphosphonate, et en particulier d'ibandronate (connu auparavant sous la désignation BM21.0955), servant à la préparation d'un agent de traitement de maladies d'activation chronique du système immunitaire et à la préparation d'un agent anti-inflammatoire pour le traitement de troubles inflammatoires.
PCT/GB1997/001037 1996-04-17 1997-04-15 Bisphosphonates utilises comme agents anti-inflammatoires Ceased WO1997038696A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU25186/97A AU2518697A (en) 1996-04-17 1997-04-15 Bisphosphonates as anti-inflammatory agents

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9607945.4 1996-04-17
GBGB9607945.4A GB9607945D0 (en) 1996-04-17 1996-04-17 Bisphosponates as Anti-inflammatory agents

Publications (1)

Publication Number Publication Date
WO1997038696A1 true WO1997038696A1 (fr) 1997-10-23

Family

ID=10792210

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1997/001037 Ceased WO1997038696A1 (fr) 1996-04-17 1997-04-15 Bisphosphonates utilises comme agents anti-inflammatoires

Country Status (3)

Country Link
AU (1) AU2518697A (fr)
GB (2) GB9607945D0 (fr)
WO (1) WO1997038696A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU754862B2 (en) 1998-12-23 2002-11-28 Bioagency Ag Use of bisphosphonates for the prevention and treatment of infectious processes
DE60235085D1 (de) 2001-07-16 2010-03-04 Univ Paris Xiii Herstellungsverfahren von derivate von bisphosphonaten

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992003451A1 (fr) * 1990-08-21 1992-03-05 The Upjohn Company Derives d'acide bisphosphonique utilises comme agents anti-arthritiques
WO1994009017A1 (fr) * 1992-10-09 1994-04-28 The Upjohn Company Esters de biphosphonate de pyrimidine et acides (alcoxymethylphosphonyl)alkyle phosphoniques utilises comme anti-inflammatoires
WO1996023505A1 (fr) * 1995-01-30 1996-08-08 Olli Pekka Teronen Inhibition de la degradation des composants proteiniques de la matrice des tissus conjonctifs, chez les mammiferes

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2813121A1 (de) * 1977-03-29 1978-10-12 Procter & Gamble Verwendung von dichlormethan-diphosphonatverbindungen bei der bekaempfung von collagen-erkrankungen und zur wundheilung
US4634691A (en) * 1980-10-07 1987-01-06 The Procter & Gamble Company Method for inhibiting tumor metastasis
DE3623397A1 (de) * 1986-07-11 1988-01-14 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992003451A1 (fr) * 1990-08-21 1992-03-05 The Upjohn Company Derives d'acide bisphosphonique utilises comme agents anti-arthritiques
US5412141A (en) * 1990-08-21 1995-05-02 The Upjohn Company Bisphosphonic acid derivatives as anti-arthritic agents
WO1994009017A1 (fr) * 1992-10-09 1994-04-28 The Upjohn Company Esters de biphosphonate de pyrimidine et acides (alcoxymethylphosphonyl)alkyle phosphoniques utilises comme anti-inflammatoires
WO1996023505A1 (fr) * 1995-01-30 1996-08-08 Olli Pekka Teronen Inhibition de la degradation des composants proteiniques de la matrice des tissus conjonctifs, chez les mammiferes

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
"bm21.0955", DRUGS OF THE FUTURE, vol. 20, no. 1, 1995, pages 71 - 72, XP000676639 *
FLEISCH: "bisphosphonates", DRUGS, vol. 42, no. 6, 1991, pages 919 - 944, XP000676675 *
ORR ET AL.: "tumor-bone interactions in skeletal metastasis", CLINICAL ORTHOPAEDICS AND RELATED RESEARCH, vol. 312, 1995, pages 19 - 33, XP000676626 *
SANTY ET AL.: "IL-6 and TNF alpha levels after bisphosphonates treatment...", BONE, vol. 18, no. 2, February 1996 (1996-02-01), pages 133 - 139, XP000676631 *

Also Published As

Publication number Publication date
GB9707570D0 (en) 1997-06-04
AU2518697A (en) 1997-11-07
GB2312165A (en) 1997-10-22
GB9607945D0 (en) 1996-06-19

Similar Documents

Publication Publication Date Title
Wong et al. The mechanisms of action of cyclosporin A in the treatment of psoriasis
Selby et al. Tumour necrosis factor in man: clinical and biological observations
Favre et al. Cyclosporin in the treatment of lupus nephritis
US7741276B2 (en) Use of interleukin-18 inhibitors to inhibit tumor metastasis
Opp et al. Human immunodeficiency virus envelope glycoprotein 120 alters sleep and induces cytokine mRNA expression in rats [published errata appear in Am J Physiol 1996 Aug; 271 (2 Pt 2): section R following table of contents and 1996 Dec; 271 (6 Pt 3): section R following table of contents]
Haddad et al. Amiloride Blockades Lipopolysaccharide-Induced Proinflammatory Cytokine Biosynthesis in an I κ B-α/NF-κ B–Dependent Mechanism: Evidence for the Amplification of an Antiinflammatory Pathway in the Alveolar Epithelium
Paquet et al. Would cyclosporin A be beneficial to mitigate drug-induced toxic epidermal necrolysis?
WON et al. Cyclosporin A inhibits keratinocyte cytokine gene expression
Chokoeva et al. Pyoderma gangrenosum—a novel approach?
Rainsford et al. Effects of 5− lipoxygenase inhibitors on interleukin production by human synovial tissues in organ culture: comparison with interleukin− 1− synthesis inhibitors
De Wet et al. Pyoderma gangrenosum, acne, and suppurative hidradenitis syndrome in end-stage renal disease successfully treated with adalimumab
FUJIWARA et al. Inhibition of proliferative responses and interleukin 2 productions by salazosulfapyridine and its metabolites
Knerr et al. Chronic inflammation and hemodialysis reduce immune competence of peripheral blood leukocytes in end-stage renal failure patients
Nold et al. IL-18BPa: Fc cooperates with immunosuppressive drugs in human whole blood
WO1997038696A1 (fr) Bisphosphonates utilises comme agents anti-inflammatoires
Thomsen et al. Flavone acetic acid (FAA) with recombinant interleukin-2 (TIL-2) in advanced malignant melanoma. II: Induction of nitric oxide production
De Kimpe et al. Role for intracellular platelet‐activating factor in the circulatory failure in a model of Gram‐positive shock
Pettipher et al. Resident joint tissues, rather than infiltrating neutrophils and monocytes, are the predominant sources of TNF-α in zymosan-induced arthritis
JPH0359044B2 (fr)
WO2000015249A1 (fr) Traitement de la maladie de kaposi avec il-12
MXPA02007683A (es) Metodo para tratar o inhibir la lesion celular o muerte celular.
Fieren Mechanisms regulating cytokine release from peritoneal macrophages during continuous ambulatory peritoneal dialysis
AU757489B2 (en) Method for inhibiting cytokine production by cells
EP1038529A2 (fr) Agent permettant d'augmenter la production de chimiokine
Mazuski et al. Effects of cytokine antagonists on the hepatic acute-phase response

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN YU AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 97536863

Format of ref document f/p: F

NENP Non-entry into the national phase

Ref country code: CA